Lung Cancer

A recent review presents updated treatment strategies for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.

A review of multiple clinical trials in patients with non–small-cell lung cancer and brain metastases finds adagrasib effectively penetrates the central nervous system, resulting in good response rates.

Study determines that permanently discontinuing immune checkpoint inhibitors after grade ≥2 immune-related adverse events is an appropriate response for patients with stage IV non–small-cell lung cancer.

In patients with non–small-cell lung cancer, broad and rapid genomic profiling are recommended for use at all stages of clinical management to improve patient outcomes.

Sotorasib in a patient with KRAS G12C–mutated lung cancer and brain metastases resolved or shrank brain lesions and improved mental status.

Despite advantages for molecular testing for non–small-cell lung cancer, the testing rate remains low, with white patients and female patients having a higher likelihood of undergoing molecular testing.

Maintaining quality of life and independence was found to be a high priority for patients with non–small-cell lung cancer and should be regularly assessed by the care team.

In a recent study, circulating tumor cells were found to act as a precise biomarker in early assessment and therapy monitoring in patients with lung cancer.

All patient ethnic/racial groups demonstrated improved clinical outcome when experiencing immune-related adverse events while receiving therapy with an immune checkpoint inhibitor, but Hispanic patients appear to derive less benefit.

In a recent trial of patients with advanced non–small-cell lung cancer, liquid biopsy led to faster molecular results and shortened time to treatment.